[go: up one dir, main page]

RS54045B1 - Pyrazolylaminopyridines as inhibitors of fak - Google Patents

Pyrazolylaminopyridines as inhibitors of fak

Info

Publication number
RS54045B1
RS54045B1 RS20150365A RSP20150365A RS54045B1 RS 54045 B1 RS54045 B1 RS 54045B1 RS 20150365 A RS20150365 A RS 20150365A RS P20150365 A RSP20150365 A RS P20150365A RS 54045 B1 RS54045 B1 RS 54045B1
Authority
RS
Serbia
Prior art keywords
pyrazolylaminopyridines
fak
inhibitors
amino
methyloxy
Prior art date
Application number
RS20150365A
Other languages
Serbian (sr)
Inventor
Jerry Leroy Adams
Thomas H. Faitg
Neil W. Johnson
Hong Lin
Jiri Kasparec
Mark Mellinger
Ren Xie
Xin Peng
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54045(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of RS54045B1 publication Critical patent/RS54045B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

2-[(5-hloro-2-{[3-metil-1-(1-metiletil)-1H-pirazol-5-il]amino}-4-piridinil)amino]-N-(metiloksi)benzamid, koji je jedinjenje formule (Ia)ili njegova so.Prijava sadrži još 14 patentnih zahteva.2 - [(5-chloro-2 - {[3-methyl-1- (1-methylethyl) -1H-pyrazol-5-yl] amino} -4-pyridinyl) amino] -N- (methyloxy) benzamide, which is a compound of formula (Ia) or a salt thereof. The application contains 14 more claims.

RS20150365A 2008-10-27 2009-10-27 Pyrazolylaminopyridines as inhibitors of fak RS54045B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15
PCT/US2009/062163 WO2010062578A1 (en) 2008-10-27 2009-10-27 Pyrazolylaminopyridines as inhibitors of fak

Publications (1)

Publication Number Publication Date
RS54045B1 true RS54045B1 (en) 2015-10-30

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20150365A RS54045B1 (en) 2008-10-27 2009-10-27 Pyrazolylaminopyridines as inhibitors of fak

Country Status (36)

Country Link
US (6) US20100113475A1 (en)
EP (1) EP2421537B1 (en)
JP (1) JP5642689B2 (en)
KR (1) KR101512217B1 (en)
CN (1) CN102264371B (en)
AR (1) AR073993A1 (en)
AU (1) AU2009320144B2 (en)
BR (1) BRPI0920053B8 (en)
CA (1) CA2741760C (en)
CL (1) CL2011000933A1 (en)
CO (1) CO6361929A2 (en)
CR (1) CR20110264A (en)
CY (1) CY1116399T1 (en)
DK (1) DK2421537T3 (en)
DO (1) DOP2011000113A (en)
EA (1) EA021927B1 (en)
ES (1) ES2539835T3 (en)
HK (1) HK1161680A1 (en)
HR (1) HRP20150531T1 (en)
IL (1) IL212444A (en)
JO (1) JO3067B1 (en)
MA (1) MA32727B1 (en)
MX (1) MX2011004369A (en)
MY (1) MY161890A (en)
NZ (1) NZ592477A (en)
PE (1) PE20110941A1 (en)
PL (1) PL2421537T3 (en)
PT (1) PT2421537E (en)
RS (1) RS54045B1 (en)
SG (1) SG195608A1 (en)
SI (1) SI2421537T1 (en)
SM (1) SMT201500157B (en)
TW (1) TWI454467B (en)
UY (1) UY32200A (en)
WO (1) WO2010062578A1 (en)
ZA (1) ZA201102892B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JP2014503589A (en) * 2011-01-26 2014-02-13 グラクソスミスクライン、インテレクチュアル、プロパティー、リミテッド combination
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2840211A1 (en) * 2011-06-28 2013-01-03 Glaxosmithkline Intellectual Property (No.2) Limited Method of administration and treatment
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
CA2991044A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CN108948019B (en) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 Focal adhesion kinase inhibitors and uses thereof
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
US20210030703A1 (en) 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (en) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 Benzimidazoles compound and its preparation method and application
EP3856190A4 (en) * 2018-09-27 2022-09-21 Dana Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
WO2020190774A1 (en) 2019-03-15 2020-09-24 The General Hospital Corporation Novel small molecule inhibitors of tead transcription factors
CN113387947B (en) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 Pyrazolopyridine derivatives that modulate estrogen receptor synthesis activity
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
ATE310018T1 (en) * 1998-09-08 2005-12-15 Agouron Pharma MODIFICATIONS OF VEGF RECEPTOR-2 PROTEIN AND METHODS OF USE THEREOF
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP1660458B1 (en) * 2003-08-15 2012-01-25 Novartis AG 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
US8501763B2 (en) * 2007-03-16 2013-08-06 The Scripps Research Institute Inhibitors of focal adhesion kinase
EP2249650A4 (en) * 2008-02-19 2012-01-11 Glaxosmithkline Llc Anilinopyridines as inhibitors of fak
CN102124000B (en) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 Pyridine compounds

Also Published As

Publication number Publication date
BRPI0920053A2 (en) 2015-12-15
NZ592477A (en) 2013-01-25
DK2421537T3 (en) 2015-06-22
US9446034B2 (en) 2016-09-20
MY161890A (en) 2017-05-15
AR073993A1 (en) 2010-12-15
SMT201500157B (en) 2015-09-07
CA2741760C (en) 2016-02-23
AU2009320144B2 (en) 2013-11-21
PE20110941A1 (en) 2012-02-08
PT2421537E (en) 2015-07-03
KR101512217B1 (en) 2015-04-15
US20110269774A1 (en) 2011-11-03
US20140107131A1 (en) 2014-04-17
TWI454467B (en) 2014-10-01
WO2010062578A1 (en) 2010-06-03
DOP2011000113A (en) 2011-07-15
CA2741760A1 (en) 2010-06-03
MA32727B1 (en) 2011-10-02
AU2009320144A1 (en) 2010-06-03
CO6361929A2 (en) 2012-01-20
EP2421537A1 (en) 2012-02-29
US20150265589A1 (en) 2015-09-24
CY1116399T1 (en) 2017-02-08
US20160095841A1 (en) 2016-04-07
US20110207743A1 (en) 2011-08-25
UY32200A (en) 2010-05-31
EA021927B1 (en) 2015-09-30
MX2011004369A (en) 2011-05-25
EP2421537A4 (en) 2012-06-13
US20100113475A1 (en) 2010-05-06
SG195608A1 (en) 2013-12-30
BRPI0920053B8 (en) 2021-05-25
ES2539835T3 (en) 2015-07-06
IL212444A (en) 2015-11-30
SI2421537T1 (en) 2015-06-30
ZA201102892B (en) 2012-02-29
CN102264371B (en) 2013-10-02
TW201028394A (en) 2010-08-01
US9012479B2 (en) 2015-04-21
JP5642689B2 (en) 2014-12-17
PL2421537T3 (en) 2015-08-31
BRPI0920053B1 (en) 2019-11-26
HRP20150531T1 (en) 2015-06-19
CL2011000933A1 (en) 2011-10-21
KR20110080172A (en) 2011-07-12
CN102264371A (en) 2011-11-30
JP2012506876A (en) 2012-03-22
HK1161680A1 (en) 2012-08-03
IL212444A0 (en) 2011-06-30
JO3067B1 (en) 2017-03-15
EA201170617A1 (en) 2011-12-30
CR20110264A (en) 2011-10-04
EP2421537B1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
RS54045B1 (en) Pyrazolylaminopyridines as inhibitors of fak
EA201300200A1 (en) N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
EA201690598A1 (en) AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS
EA201700230A1 (en) DETERMINED AMINOPYRIDINES, COMPOSITIONS ON THEIR BASIS AND METHODS OF THEIR APPLICATION
EA201000113A1 (en) PYRAZOL COMPOUNDS
EA200702670A1 (en) PREPARATION OF THYENOPYRIDINE INHIBITOR OF PLATELET AGGREGATION
EA201201377A1 (en) DEFINED AMINOPIRIDAZINES, COMPOSITIONS ON THEIR BASIS AND METHODS OF THEIR USE
SMP201100019B (en) Organic compounds
RS54123B1 (en) Therapeutic combination comprising dolutegravir, abacavir and lamivudine
RS53301B (en) Thioacetate compounds, compositions and methods of use
WO2010105179A3 (en) Inhibitors of beta-secretase
RS54386B1 (en) Antiviral compounds
RS54526B1 (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EA201070451A1 (en) AMIDE CONNECTIONS
RS53688B1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
RS52716B (en) Hydrobenzamide derivatives as inhibitors of hsp90
RS53617B1 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
EA201190320A1 (en) HETEROCYCLIC SULPHONAMIDES, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS
PT2323972E (en) C7-fluoro substituted tetracycline compounds
BRPI0916385A2 (en) alkylthiazole carbamate derivatives, their preparation and their therapeutic application
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
EA201000257A1 (en) NEW METHOD OF SYNTHESIS (7-METHOXY-L-NAFTHYL) ACETONITRILE AND APPLICATION IN THE SYNTHESIS OF AGOMELATINE
WO2010129057A3 (en) Tetracycline compounds
WO2011025982A3 (en) Tetracycline compounds